PiclideNOSon 是一种具有口服活性的，选择性的腺苷 A3 受体激动剂。它在不同类型的癌细胞如黑色素瘤、白血病中表现出抗增殖和诱导凋亡的作用，可研究自身免疫性炎症疾病和 COVID-19。

Piclidenoson, a selective agonist of adenosine A3 receptor(EC50 values of 0.11 μM), induces robust anti-inflammatory effect in psoriasis patients.

Piclidenoson inhibited the proliferation of HaCat cells through deregulation of the NF-κB signaling pathway, leading to a decrease in interleukin-17 and interleukin-23 expression levels[1].

[3H]-Thymidine incorporation assay was used to evaluate cell growth.?HaCat cells (2500 cells/well) were incubated with piclidenoson 10?nM and MRS 1523 (50?nM) in 96-well plate for 48 hours.?For the last 24 hours of incubation, each well was pulsed with 1?mCi [3H]-thymidine.?Cells were harvested, and the [3H]-thymidine uptake was determined in an LKB liquid scintillation counter (LKB, Piscataway, NJ, USA).?These experiments were repeated at least 4 times[1].

152918-18-8

C18H19IN6O4

510.29

IB-MECA;CF-101

DMSO:45 mg/mL (88.19 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years